3 Pharma Ingredients Maker, Utility Vehicles Maker and Footwear Retailer Stocks With a Strong Future Roadmap: Neuland Laboratories, Force Motors and Bata India

Drug ingredient, vehicle and footwear stocks offer a focused view of a sector where demand keeps widening. Neuland Laboratories, Force Motors and Bata India cover a pharma ingredients maker, a utility vehicles maker and a footwear retailer.

This list covers three drug ingredient, vehicle and footwear stocks with complete current figures: Neuland Laboratories, Force Motors and Bata India. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Drug Ingredient, Vehicle and Footwear Stocks?

Drug ingredient, vehicle and footwear stocks are listed companies that make active pharmaceutical ingredients and custom molecules for global drug firms, build utility vehicles, vans and engines, and sell branded footwear through stores across many cities. Their earnings depend on drug sourcing, vehicle demand and consumer spending.

Drug Ingredient, Vehicle and Footwear Stocks at a Glance

On valuation, Force Motors trades at a P/E below the industry P/E, while Neuland Laboratories and Bata India trade above it, which reflects the growth the market already expects. Readers comparing drug ingredient, vehicle and footwear stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Drug Ingredient, Vehicle and Footwear Stocks Have a Strong Roadmap in India?

Drug ingredient, vehicle and footwear stocks have a strong roadmap in India because growing global sourcing of pharma ingredients, steady demand for utility vehicles and rising demand for branded footwear keep widening the market for these companies.

• Pharma ingredients. Drug makers need reliable specialty inputs.
• Utility vehicles. Fleets and families need versatile vehicles.
• Footwear. Shoppers upgrade to branded footwear.

Why Neuland Laboratories Features Among These Drug Ingredient, Vehicle and Footwear Stocks

Among the drug ingredient, vehicle and footwear stocks on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.

Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.

Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.

Why Force Motors Features Among These Drug Ingredient, Vehicle and Footwear Stocks

Among the API maker, tempo traveller and shoe brand shares on this list, Force Motors, based in Pune, makes light commercial vehicles such as the Traveller and Gurkha, and supplies engines and axles to global carmakers.

The company has a return on equity of 25.2%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 23,296 crore. The stock trades at a P/E of 18.6, below the industry P/E of 24.1.

Revenue rose from Rs 3,292 crore in FY22 to Rs 9,168 crore in FY26, a compound annual growth rate of 29.2%. Net profit grew from Rs 801 crore in FY25 to Rs 1,212 crore in FY26, a rise of 51.3%. In the June 2026 quarter, revenue grew 6.7% year on year to Rs 2,478 crore, while net profit rose 22.8% to Rs 217 crore.

Roadmap: Its traveller and ambulance range, defence vehicle supply and contract manufacturing for international partners give it several growth routes. It has no debt on its books, which leaves room for investment in new models.

What to watch: Track order flow from state transport and defence customers.

Why Bata India Features Among These Drug Ingredient, Vehicle and Footwear Stocks

Among the three companies on this list, Bata India is the country's largest footwear retailer, selling under the Bata, Hush Puppies, Power and other brands through a large network of company-owned and franchised stores.

Revenue rose from Rs 2,444 crore in FY22 to Rs 3,595 crore in FY26, a compound annual growth rate of 10.1%. Net profit grew from Rs 103 crore in FY22 to Rs 134 crore in FY26, which works out to a compound annual growth rate of 6.8%.

In the June 2026 quarter, revenue grew 4.0% year on year to Rs 997 crore, while net profit rose 23.0% to Rs 64.0 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.87 and a market capitalisation of Rs 8,187 crore. The stock trades at a P/E of 56.0, above the industry P/E of 37.0.

Roadmap: The company is widening its range into sports, casual and premium footwear and adding stores in smaller towns. A trusted brand and deep retail reach support steady demand.

What to watch: Follow store additions, premium product mix and same-store sales.

Neuland Laboratories vs Force Motors vs Bata India on Key Financials

The table below sets the three drug ingredient, vehicle and footwear stocks side by side on revenue, profit and margin, using reported figures.

Force Motors posts the highest return on equity in this group at 25.2%. Force Motors combines the largest FY26 revenue at Rs 9,168 crore with the fastest revenue growth, a 29.2% compound annual rate. A useful habit with drug ingredient, vehicle and footwear stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Drug Ingredient, Vehicle and Footwear Stocks

Every theme carries risks that deserve a check before any decision. For these drug ingredient, vehicle and footwear stocks, the main points are:

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Production cycles. Vehicle output can vary with demand.
• Footfall and spending. Store sales follow consumer mood and seasons.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter drug ingredient, vehicle and footwear stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Drug Ingredient, Vehicle and Footwear Stocks

Drug ingredient, vehicle and footwear stocks reward patient research into demand, execution and financial strength. Neuland Laboratories, Force Motors and Bata India each have a clear plan to grow. Based on the 11 November 2026 close, Neuland Laboratories trades at Rs 20,204, Force Motors at Rs 19,872 and Bata India at Rs 642.1.

Download the Univest iOS App or Univest Android App to track drug ingredient, vehicle and footwear stocks, set price alerts and get research-backed stock ideas.

What are drug ingredient, vehicle and footwear stocks?

Ans. Drug ingredient, vehicle and footwear stocks are listed companies that make active pharmaceutical ingredients and custom molecules for global drug firms, build utility vehicles, vans and engines, and sell branded footwear through stores across many cities. Their earnings depend on drug sourcing, vehicle demand and consumer spending. This list looks at three of them, Neuland Laboratories, Force Motors and Bata India, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which drug ingredient, vehicle and footwear stocks are covered in this list?

Ans. This list covers Neuland Laboratories, Force Motors and Bata India. Based on the 11 November 2026 close, Neuland Laboratories traded at Rs 20,204, Force Motors at Rs 19,872 and Bata India at Rs 642.1. Their return on equity ranges from 10.4% to 25.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.1% to 29.2%.

Why do drug ingredient, vehicle and footwear stocks have a strong future roadmap in India?

Ans. Drug ingredient, vehicle and footwear stocks have a strong roadmap in India because growing global sourcing of pharma ingredients, steady demand for utility vehicles and rising demand for branded footwear keep widening the market for these companies. The main drivers are as follows. Pharma ingredients. Drug makers need reliable specialty inputs. Utility vehicles. Fleets and families need versatile vehicles. Footwear. Shoppers upgrade to branded footwear. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Neuland Laboratories performed financially?

Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

How has Force Motors performed financially?

Ans. Revenue rose from Rs 3,292 crore in FY22 to Rs 9,168 crore in FY26, a compound annual growth rate of 29.2%. Net profit grew from Rs 801 crore in FY25 to Rs 1,212 crore in FY26, a rise of 51.3%. In the June 2026 quarter, revenue grew 6.7% year on year to Rs 2,478 crore, while net profit rose 22.8% to Rs 217 crore. The company has a return on equity of 25.2%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 23,296 crore. The stock trades at a P/E of 18.6, below the industry P/E of 24.1. Looking ahead, its traveller and ambulance range, defence vehicle supply and contract manufacturing for international partners give it several growth routes. It has no debt on its books, which leaves room for investment in new models.

How has Bata India performed financially?

Ans. Revenue rose from Rs 2,444 crore in FY22 to Rs 3,595 crore in FY26, a compound annual growth rate of 10.1%. Net profit grew from Rs 103 crore in FY22 to Rs 134 crore in FY26, which works out to a compound annual growth rate of 6.8%. In the June 2026 quarter, revenue grew 4.0% year on year to Rs 997 crore, while net profit rose 23.0% to Rs 64.0 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.87 and a market capitalisation of Rs 8,187 crore. The stock trades at a P/E of 56.0, above the industry P/E of 37.0. Looking ahead, the company is widening its range into sports, casual and premium footwear and adding stores in smaller towns. A trusted brand and deep retail reach support steady demand.

What risks should investors check before buying drug ingredient, vehicle and footwear stocks?

Ans. Investors should check a few risks before buying drug ingredient, vehicle and footwear stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Production cycles. Vehicle output can vary with demand. Footfall and spending. Store sales follow consumer mood and seasons. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of drug ingredient, vehicle and footwear stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.